Bendamustine-rituximab: A cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales

Journal of Medical Economics

Volumn 17, Issue 2, 2014, Pages 111-124

  Dewilde, Sarah ^a   Woods, Beth ^b   Castaigne, Jean Gabriel ^c   Parker, Christopher ^b   Dunlop, William ^c  

^a SHE   (Belgium)

^b ICON PLC   (United Kingdom)

^c Mundipharma International Limited   (United Kingdom)

Author keywords

Bendamustine; CHOP; Cost effectiveness; CVP; Non Hodgkin's lymphoma; Patient level simulation; Rituximab

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENGLAND; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; PREDNISONE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VINCRISTINE; WALES;

EID: 84892757055     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.873044     Document Type: Article

References (37)

1. Cancer Research UK. Non-Hodgkin lymphoma incidence statistics. http:// www.cancerresearchuk.org/cancer-info/cancerstats/types/nhl/incidence. Accessed November 27, 2013
2. Ferlay J, Shim H-R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
3. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Ann Oncol 1999;10:1419-32
4. Cella D, Mahon S, Donavan M. Cancer recurrence as a traumatic event. Behav Med 1990;16:15-22
5. Cancer Research UK. Non-Hodgkin lymphoma survival doubles since early 1970s. Press release 23 May 2013. London. www.cancerreasearchuk.org/ cancer-info/news/archive/pressrelease/. Accessed November 27, 2013
6. National Institute for Health and Clinical Excellence. Rituximab for the first-line treatment of stage III-IV follicular lymphoma: review of NICE technology appraisal guidance 110. NICE Technology Appraisal Guidance 243: January 2012. London. http://publications.nice.org.uk/rituximab-for-thefirst- line-treatment-of-stage-iii-iv-follicular-lymphoma-ta243. Accessed November 27, 2013
7. Mundipharma International Limited. Data on file. Mundipharma Europe Oncology Analyzer. August 2012
8. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492-501
9. Rummel MJ, Al-Batran SE, Kim S-Z, et al. Bendamustine plus rituximab is effective and has a favourable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383-9
10. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473-9
11. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204-10
12. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116:106-14
13. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-10
14. Papaioannou D, Rafia R, Rathbone J, et al. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Health Technol Assess 2012;16:1-253
15. R Development Core Team. The R project for statistical computing. Vienna. http://www.r-project.org. Accessed November 27, 2013
16. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23
17. National Institute for Health and Clinical Excellence. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma. NICE Technology Appraisal Guidance 226: June 2011. http://publications.nice.org. uk/rituximab-for-the-first-line-maintenance-treatment-of-follicular-nonhodgkins- lymphoma-ta226. Accessed November 27, 2013
18. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2010;377:42-51
19. Roche Products Limited. MabThera summary of product characteristics. 2013. Leatherhead, Surrey. http://www.medicines.org.uk/emc. Accessed November 27, 2013
20. National Institute for Health and Clinical Excellence. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma: review of technology appraisal guidance 37. NICE Technology Appraisal Guidance 137: February 2008. http://publications.nice.org.uk/ rituximab-for-the-treatment-of-relapsed-or-refractory-stage-iii-or-iv- follicular-non-hodgkins-ta137. Accessed November 27, 2013
21. Flinn IW, van der Jagt R, Kahl BS, et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (CVP-R) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP-R) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): the BRIGHT study. Blood (ASH Annual Meeting Abstracts) 2012;120:abstract 902
22. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26
23. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239-41
24. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of Martingale-based residuals. Biometrika 1993;80:557-72
25. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32
26. van Oers MH, Van GM, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-8
27. Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:3614-20
28. Wild D, Pettengell R, Lewis G. Utility elicitation in patients with follicular lymphoma. Poster presented at ISPOR 9th Annual European Congress; 2006 Oct 28-31; Copenhagen, Denmark
29. Joint Formulary Committee. British National Formulary [online]. 2012. London. http://www.medicinescomplete.com/mc/bnf/current/. Accessed January 28, 2013
30. NHS Reference Costs 2010-11. London: Department of Health. http:// www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-131140. Accessed November 27, 2013
31. Guest JF, Ruiz FJ, Greener MJ, et al. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care 2006;15:65-73
32. Federico M, Luminari S, Dondi A, et al. CVP-R vs. CHOP-R vs R-FM for the initial treatment of patients with advanced-stage follicular lymphoma. Final results of the FOLL05 trial from the Fondazione Italiana Linfomi. Presented at the ASCO Annual Meeting; 2012 Jun 1-5; Chicago, IL, USA. http://issuu.com/spom/ docs/1-8006-federicorev. Accessed September 13, 2013
33. National Institute of Clinical Excellence. Guide to the methods of technology appraisal. 2008. London. http://www.nice.org.uk/media/B52/A7/ TAMethods GuideUpdatedJune2008.pdf. Accessed November 27, 2013
34. Personal Social Services Research Unit. Unit costs of health and social care 2012. Canterbury, Kent. http://www.pssru.ac.uk/project-pages/unit-costs/ 2012/. Accessed November 27, 2013
35. Dreyling M, Ghielmini M, Marcus R, et al; on behalf of the ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(6 Suppl):vi59-63
36. Burke JM, van der Jagt RH, Kahl BS, et al. Differences in quality of life between bendamustine plus rituximab compared with standard first-line treatments in patients with previously untreated advanced indolent non-Hodgkin's lymphoma or mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2012;120:abstract 155
37. Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013;31:1506-13